Hangzhou Jeci Biochem Technology Co., Ltd.yog nyob rau hauv Hangzhou, Zhejiang Province. Peb tau cog lus rau kev muag khoom ntawm cov khoom xyaw tshuaj nquag thiab cov tshuaj intermediates, koom tes R & D, kev tsim khoom, kev muag khoom thiab kev pabcuam nrog rau kev xa khoom ntawm cov khoom siv raw khoom.
Peb lub tuam txhab muaj ntau yam kev tsim nyog thiab cov ntawv pov thawj tiav, muaj ntau yam tshuaj intermediates thiab cov tshuaj precursor, thiab feem ntau ntawm cov khoom txaus ntshai ua lag luam tsim nyog, thiab tau ua tiav ntshuam thiab xa tawm tsim nyog, lub tuam txhab cov khoom raug muag thoob plaws ntiaj teb, thiab ua haujlwm rau ntshuam thiab xa tawm ntawm ntau yam khoom xws li tshuaj lom neeg.
Lub tuam txhab feem ntau yog koom nrog hauv kev lag luam wholesale, khw muag khoom, khoom siv roj ntsha, tshuaj intermediates, thawj- cov khoom siv kho mob, cov khoom siv roj av, cov khoom siv roj hmab, cov khoom siv yas, cov khoom siv roj ntsha, cov tshuaj biochemical test reagents thiab consumables, tshuaj reagents; Kev lag luam tshuaj (ua haujlwm nrog cov ntawv tso cai siv tau) Ntshuam thiab xa tawm cov khoom thiab thev naus laus zis (tshwj tsis yog cov phiaj xwm txwv tsis pub los ntawm lub teb chaws txoj cai lij choj thiab kev tswj hwm kev tswj hwm, thiab cov kev cai lij choj thiab kev tswj hwm tau teev tseg tias cov haujlwm uas txwv kev ua haujlwm tsuas yog ua tau tom qab tau txais daim ntawv tso cai). (Cov phiaj xwm raug pom zoo raws li txoj cai lij choj yuav raug ua tom qab pom zoo los ntawm cov tuam tsev muaj feem cuam tshuam).Peb, Jeci Biochem, tuaj yeem muab cov khoom nruab nrab ntsig txog cov tshuaj tiv thaiv kab mob siab. Kev nug tau txais tos!
Tsis ntev los no, AstraZeneca tau tshaj tawm tias daim ntawv thov kev lag luam rau nws txoj kev tshawb nrhiav kev kho Baxdrostat tau txais los ntawm US FDA thiab tau tso cai ua ntej Kev Tshawb Fawb. Nws yog npaj los ua ib qho ntxiv- ntawm kev kho mob rau lwm cov tshuaj tiv thaiv kab mob rau cov neeg laus cov neeg mob ntshav siab resistant (tsis tswj lossis kho- tiv taus) uas nws cov ntshav siab tsis tuaj yeem txo qis los ntawm cov tshuaj uas twb muaj lawm. FDA cia siab tias yuav ua kom tiav nws qhov kev tshuaj xyuas nyob rau hauv lub quarter thib ob ntawm 2026. Yog tias pom zoo, Baxdrostat yuav dhau los ua lub ntiaj teb thawj kev lag luam aldosterone synthase inhibitor (ASI), uas yog qhov ua tiav ntawm kev kho mob ntshav siab.
Baxdrostat is a highly selective, potent oral small-molecule aldosterone synthase inhibitor acquired by AstraZeneca through its acquisition of CinCor Pharma. It directly lowers aldosterone levels by specifically inhibiting the last three rate-limiting steps of aldosterone synthesis in the adrenal glands. Unlike traditional antihypertensives such as beta-blockers or ARBs, Baxdrostat's innovation lies in precisely targeting the aldosterone synthesis pathway, with >100-fold xaiv tshaj cortisol synthesis enzymes, yog li zam kev phiv cuam tshuam nrog cortisol dysregulation. Cov txheej txheem no tshwj xeeb tshaj yog haum rau cov neeg mob uas nws cov ntshav siab tseem tsis tau tswj xyuas tom qab kev kho mob nrog ntau yam tshuaj uas twb muaj lawm, muab cov tshuaj tshiab rau lawv.
Daim ntawv thov kev lag luam rau Baxdrostat yog raws li cov txiaj ntsig los ntawm Phase III BaxHTN txoj kev tshawb fawb. Qhov kev sim sau npe 796 cov neeg mob uas tiv taus kub siab thiab pom tias:
Thaum 12 lub lis piam, pawg koob tshuaj 2 mg tau ua tiav qhov txo qis hauv cov ntshav siab systolic (SBP) ntawm 15.7 mmHg, 1 mg pawg 14.5 mmHg, piv nrog tsuas yog 5.8 mmHg hauv pawg placebo. Tom qab kho cov placebo, pawg 2 mg thiab 1 mg tau ua tiav qhov txo qis ntawm 9.8 mmHg thiab 8.7 mmHg, ntsig txog (p.< 0.001).
Hauv 24-teev ambulatory BP saib xyuas, Baxdrostat 2 mg pab pawg txo SBP hmo ntuj los ntawm 13.9 mmHg (p< 0.0001), effectively covering the high-risk early morning period for cardiovascular events.
Tus nqi ntawm BP tswj (SBP< 130 mmHg) increased nearly threefold, with 71% of patients achieving sustained 24‑hour BP control.
Hais txog kev nyab xeeb, Baxdrostat tau txais txiaj ntsig zoo, tsis muaj cov xwm txheej tsis txaus ntseeg; feem ntau cov kev phiv tshwm sim yog mob me. Cov ntaub ntawv no tau nthuav tawm ntawm 2025 European Society of Cardiology (ESC) Congress thiab ib txhij luam tawm hauvNew England Journal of Medicine.
Kev ua lag luam muaj peev xwm rau cov tshuaj antihypertensive yog loj heev. Raws li PharmCube cov ntaub ntawv, kev muag khoom ntawm cov tshuaj antihypertensive tshuaj nyob thoob plaws Tuam Tshoj peb lub ntsiab lus tseem ceeb tshaj RMB 78.9 billion hauv 2024. Thoob ntiaj teb, muaj 1.4 billion tus neeg mob ntshav siab, kwv yees li 25% ntawm cov neeg muaj aldosterone dysregulation, thaum resistant kub siab xav tau nyiaj rau 30% -50%, unmetting clination.
Tam sim no, kev sib tw hauv ASI teb yog cua sov. Ntxiv rau Baxdrostat, Mineralys 'Lorundrostat thiab Boehringer Ingelheim's BI 690517 yog ob qho tib si hauv Phase III txoj kev loj hlob, thiab cov tuam txhab hauv tsev xws li Salubris thiab Hansoh Pharma kuj tau nkag mus rau qhov chaw. Nrog rau nws qhov Kev Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Lij Tshaj Tawm
Rau AstraZeneca, Baxdrostat tsis yog tsuas yog kev ua txhaum ntawm kev kub siab, tab sis kuj yog tus tsav tsheb loj hlob rau nws cov hlab plawv, lub raum thiab Metabolism (CVRM) franchise. Raws li nws cov khoom lag luam blockbuster dapagliflozin ze rau patent tas sij hawm, Baxdrostat tuaj yeem ua ke nrog GLP-1 tshuaj AZD5004, lipid-txo tus neeg sawv cev AZD0780, thiab lwm yam los tsim kom muaj "lub plawv- raum-metabolism" kho matrix. Nyob rau hauv lub neej yav tom ntej, yog tias nws cov lus qhia nthuav dav rau lub plawv tsis ua hauj lwm thiab mob raum mob, nws yuav ntxiv dag zog rau AstraZeneca cov thawj coj hauv CVRM thiab txhawb nws lub hom phiaj ntawm $ 80 nphom hauv cov nyiaj tau los los ntawm 2030.
